ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 412

Efficacy of Shoe-Stiffening Inserts for First Metatarsophalangeal Joint Osteoarthritis: Preliminary Findings from the Simple Randomised Controlled Trial

Shannon Munteanu1, Karl Landorf1, Jodie McClelland1, Edward Roddy2, Flavia Cicuttini3, Alan Shiell4, Maria Auhl1, Jamie Allan1, Andrew Buldt1 and Hylton B. Menz1, 1School of Allied Health, La Trobe University, Bundoora, Australia, 2Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, 3Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia, 4School of Psychology and Public Health, La Trobe University, Bundoora, Australia

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: foot, foot wear, orthotics and osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: Orthopedics, Low Back Pain and Rehabilitation Poster – ACR/ARHP

Session Type: ACR/ARHP Combined Abstract Session

Session Time: 9:00AM-11:00AM

Background/Purpose: This trial assessed the efficacy of shoe-stiffening inserts for reducing pain associated with first metatarsophalangeal joint (MTPJ) osteoarthritis (OA).

Methods: One hundred participants (45 men 55 women, mean age 57.5, SD 10.3 years) with first MTPJ OA received rehabilitation therapy and were randomised to receive either (i) full-length carbon fibre shoe-stiffening inserts (Figure 1) (intervention group) or (ii) sham shoe inserts (control group). The primary outcome measure was the foot pain domain of the Foot Health Status Questionnaire (FHSQ) assessed at 12 weeks. Secondary outcome measures included the function domain of the FHSQ, severity of first MTPJ pain, general health status, use of rescue medication and co-interventions, adverse events, physical activity levels and global change in symptoms (‘moderately better’ or above considered a successful outcome). FHSQ and global change in symptoms at 12 weeks are presented here. Multiple imputation was used to replace missing data. FHSQ pain scores were analysed using analysis of covariance with the intervention group and baseline scores entered as independent variables, and global change in symptoms was analysed using absolute and relative benefit, and number needed to treat.

Results: Data were available for 91 participants at week 4 and 85 participants at week 12. FHSQ pain scores improved in both groups. There was a statistically significant difference in FHSQ pain in favour of the intervention group at 12 weeks (adjusted mean difference 7.4 points, 95% confidence interval [95% CI] 1.3 – 13.5, p=0.018). See Figure 2. Participants in the intervention group were also more likely to report that their pain was at least moderately better (successful treatment) at 12 weeks compared to the control group (61 versus 34%; absolute benefit increase 27% [95% CI 6 – 45], relative benefit increase 79% [95% CI 11 – 189]). The number needed to treat was 4 (95% CI 2 – 18).

Conclusion: Carbon fibre shoe stiffening inserts are effective at reducing pain in people with first MTPJ OA.

 

 

Figure 1. Full-length carbon fibre shoe-stiffening insert.

Figure 2. Foot Health Status Questionnaire (FHSQ) scores at baseline, week 4 and week 12 for the control and intervention groups. Higher scores indicate less foot pain.


Disclosure: S. Munteanu, None; K. Landorf, None; J. McClelland, None; E. Roddy, None; F. Cicuttini, None; A. Shiell, None; M. Auhl, None; J. Allan, None; A. Buldt, None; H. B. Menz, None.

To cite this abstract in AMA style:

Munteanu S, Landorf K, McClelland J, Roddy E, Cicuttini F, Shiell A, Auhl M, Allan J, Buldt A, Menz HB. Efficacy of Shoe-Stiffening Inserts for First Metatarsophalangeal Joint Osteoarthritis: Preliminary Findings from the Simple Randomised Controlled Trial [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/efficacy-of-shoe-stiffening-inserts-for-first-metatarsophalangeal-joint-osteoarthritis-preliminary-findings-from-the-simple-randomised-controlled-trial/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-shoe-stiffening-inserts-for-first-metatarsophalangeal-joint-osteoarthritis-preliminary-findings-from-the-simple-randomised-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology